3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Polycystic Ovary Syndrome
21
Glioblastoma
5
Endometrial Neoplasms
5
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Neoplasms
3
Leukoplakia, Oral
3
Insulin Resistance
3
Ovarian Neoplasms
2
Obesity
2
Metabolic Syndrome
2
Metabolic Diseases
2
Medulloblastoma
2
Infertility
2
Erythroplasia
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Intraductal, Noninfiltrating
2
Adenocarcinoma Of Esophagus
2
Weight Loss
1
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Thyroid Diseases
1
TP53 Y220C Mutation
1
Smoldering Multiple Myeloma
1
Sarcoma
1
Rectal Neoplasms
1
Prostate Cancer Recurrent
1
Prediabetic State
1
Posterior Fossa Ependymal Tumor
1
Interventions
Fulvestrant
5
serabelisib
2
sapanisertib
2
ribociclib
2
palbociclib
2
Paclitaxel
2
Letrozole
2
Irinotecan
2
Gemcitabine
2
Carboplatin
2
Alpelisib
2
venetoclax
1
tivozanib
1
tipifarnib
1
sotorasib
1
pembrolizumab
1
olaparib
1
niraparib
1
lorlatinib
1
liposomal doxorubicin
1
inavolisib
1
exemestane
1
encorafenib
1
ceralasertib
1
cemiplimab
1
capivasertib
1
binimetinib
1
abemaciclib
1
Taxes
1
Tamoxifen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Metformin
×
1 year
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled